Comparison · NCT03049618-5023e934
Head and Neck Cancer Cohort vs Non-Small Cell Lung Cancer Cohort: Overall Response Rate (ORR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Head and Neck Cancer Cohort vs Non-Small Cell Lung Cancer Cohort: Overall Response Rate (ORR). Trial comparisons, record NCT03049618-5023e934. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03049618-5023e934
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.24 | 0.115 | 0.434 | wilson | |
| Risk in group 2 | 0.176 | 0.0619 | 0.41 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0635 | -0.202 | 0.289 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.36 | 0.393 | 4.71 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 0.313 | 6.93 | log | |
| Number needed to treat, for one more participant with the outcome on Head and Neck Cancer Cohort than on Non-Small Cell Lung Cancer Cohort | 15.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Head and Neck Cancer Cohort | Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Correlative studies~Pembrolizumab: Given IV~Recombinant EphB4-HSA Fusion Protein: Given IV | 6 | 25 | OG000 |
| Group 2 | Non-Small Cell Lung Cancer Cohort | Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Correlative studies~Pembrolizumab: Given IV~Recombinant EphB4-HSA Fusion Protein: Given IV | 3 | 17 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Overall Response Rate (ORR)
- Description
Calculated based on the evaluable population of patients who received at least 1 dose of therapy. Overall response rate (ORR) is complete response (CR) + partial response (PR) recorded from study entry until disease progression based on RECIST v1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.
- Time frame
- Up to 22 months
- Population
- Evaluable population of patients who received at least 1 dose of therapy. No statistical analysis is performed.
Source ClinicalTrials.gov
Trial
- Title
- Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
- NCT number
- NCT03049618
- Phases
- PHASE2
- Conditions
ALK Gene Mutation, BRAF Gene Mutation, EGFR Gene Mutation, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Mutation, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein
- Lead sponsor
- University of Southern California
- Results first posted
- 2025-10-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03049618?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03049618-5023e934